Luke Maese, DO - Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/DGJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL. Upon completion of this activity, participants should be better able to: Summarize new evidence on multi-faceted strategies for ALL management based on modern chemotherapy protocols, antibody-based approaches, cellular therapy, and TKIs; Cite evidence supporting the use of novel asparaginase compounds for ALL in the context of asparaginase toxicity/hypersensitivity, including in pediatric, AYA, and adult populations; and Apply new science to the team-based management of ALL, including when managing asparaginase hypersensitivity or toxicity, developing TKI-based protocols in Ph-positive disease, or when utilizing novel immunotherapy-based approaches in patient care.